- Advertisement -
- Advertisement -
- Advertisement -

Find a job

Subscribe for free

All things Pharma


GSK’s Jose to be new ABPI President

Simon Jose, Senior Vice President and General Manager of GlaxoSmithKline, has been named as President Designate of the ABPI.

Simon will take over from the current ABPI President, Chris Brinsmead of AstraZeneca (UK), on 28 April this year. He will serve for a one‐year term, with the option of re‐election for a further 12 months.

Simon commented: “The UK Government has recognised the importance of the life science industry. It is both an engine of growth to support economic recovery and a continuing source of new medicines and vaccines to help the NHS deliver improved health during a time of limited resources. Against this backdrop, the industry itself is going through a period of considerable and rapid change.

“Patients, the NHS and society at large need access to high quality care. Innovative new medicines and vaccines form an important part of this. We should work together to develop health policies that encourage innovation, deliver value to patients and society, and help the NHS to be efficient and sustainable.”

He added that the ABPI is looking forward to continuing the close working relationship with the Government that it has enjoyed over the last couple of years, as well as with the NHS, patient groups and other important stakeholders.

Simon Jose leads the UK pharmaceuticals business of GSK, a leading supplier of medicines and vaccines to the NHS, providing treatments for conditions such as asthma, COPD, depression, diabetes, epilepsy, HIV/AIDS and infections (antibiotics), as well as a wide range of vaccines to prevent childhood illnesses.

Simon began his career with GSK in 1986 and since then has held various sales and marketing roles of increasing seniority, both in Europe and in North America, before assuming his current role in February 2008.

Commenting on Simon’s appointment, Richard Barker, Director General, ABPI, said: “This is a crucial year in our relationship with the Government. As we have seen with the recent publication of the Office for Life Sciences 2010 report, there is significant benefit to be had from collaboration between government, the NHS, academia and the industry to deliver truly tangible results. Continued commitment to this strategy is crucial to the further positive development of the life sciences sector.”

- Advertisement -


- Advertisement -



Sign up to receive our digital newsletter, for all the essential headlines, Jobs of the Week and thought-provoking features.

Claim my free subscription